Evidence supporting the presence of this FAR-independent pathway comes from patients with the inherited metabolic disease Sjögren–Larsson Syndrome (SLS) (Weustenfeld et al., 2019), characterized by a deficiency in the enzyme fatty aldehyde dehydrogenase (FALDH) which oxidizes fatty aldehydes to fatty acids (Keller et al., 2014; Weustenfeld et al., 2019). Here, ALDH3A2 is linked to metabolic disease.